Specialized proresolving lipid mediators in humans with the metabolic syndrome after n-3 fatty acids and aspirin

American Journal of Clinical Nutrition

Volumn 102, Issue 6, 2015, Pages 1357-1364

  Barden, Anne E ^a   Mas, Emilie ^a   Croft, Kevin D ^a   Phillips, Michael ^b   Mori, Trevor A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Aspirin; Metabolic syndrome; N 3 fatty acids; Protectins; Resolvins

Indexed keywords

14 HYDROXYDOCOSAHEXAENOIC ACID; 17 HYDROXYDOCOSAHEXAENOIC ACID; 18 HYDROXYEICOSAPENTAENOIC ACID; ACETYLSALICYLIC ACID; FATTY ACID; GLUCOSE; LIPID; MARESIN 1; OMEGA 3 FATTY ACID; PHOSPHOLIPID; SPECIALIZED PRORESOLVING LIPID MEDIATOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 14-HYDROXYDOCOSAHEXAENOIC ACID; 17-HYDROXY-4,7,10,13,15,19-DOCOSAHEXAENOIC ACID; 18(R)-HYDROXYEICOSAPENTAENOIC ACID; DOCOSAHEXAENOIC ACID; ENTERIC COATED TABLET; FISH OIL; ICOSAPENTAENOIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MEASUREMENT; METABOLIC SYNDROME X; PHOSPHOLIPID BLOOD LEVEL; POSTMENOPAUSE; SCREENING; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ANALOGS AND DERIVATIVES; AUSTRALIA; BLOOD; CONTROLLED CLINICAL TRIAL; DIET THERAPY; DRUG EFFECTS; ENTERIC COATED TABLET; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; YOUNG ADULT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COMBINED MODALITY THERAPY; CYCLOOXYGENASE INHIBITORS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FEMALE; FISH OILS; HUMANS; IMMUNITY, INNATE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POSTMENOPAUSE; TABLETS, ENTERIC-COATED; WESTERN AUSTRALIA; YOUNG ADULT;

EID: 84948823129     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.115.116384     Document Type: Article

References (26)

1. Chandalia M, Abate N. Metabolic complications of obesity: inflated or inflamed? J Diabetes Complications 2007;21:128-36
2. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28
3. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9
4. Tsai IJ, Beilin LJ, Puddey IB, Croft KD, Barden A. Impaired ex vivo leukotriene B4 production characterizes the metabolic syndrome and is improved after weight reduction. J Clin Endocrinol Metab 2007;92: 4747-52
5. Cannon PJ. Eicosanoids and the blood-vessel wall. Circulation 1984; 70:523-8
6. Busse WW. Leukotrienes and inflammation. Am J Respir Crit Care Med 1998;157:S210-3
7. Spite M, Claria J, Serhan CN. Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab 2014;19:21-36
8. Isobe Y, Arita M, Matsueda S, Iwamoto R, Fujihara T, Nakanishi H, Taguchi R, Masuda K, Sasaki K, Urabe D, et al. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J Biol Chem 2012;287:10525-34
9. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 2010;107:1170-84
10. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev 2011;111:5922-43
11. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009;206:15-23
12. Deng B, Wang C-W, Arnardottir HH, Li Y, Cheng C-YC, Dalli J, Serhan CN. Maresin biosynthesis and identification of maresin 2, a new anti-inflammatory and pro-resolving mediator from human macrophages. PLoS One 2014;9:e102362
13. Lopez-Huertas E. The effect of EPA and DHA on metabolic syndrome patients: a systematic review of randomised controlled trials. Br J Nutr 2012;107:S185-94
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
15. Mas E, Croft KD, Zahra P, Barden A, Mori TA. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 2012;58:1476-84
16. Barden A, Mas E, Croft KD, Phillips M, Mori TA. Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation. J Lipid Res 2014;55:2401-7
17. Oh SF, Pillai PS, Recchiuti A, Yang R, Serhan CN. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest 2011;121:569-81
18. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am J Physiol Cell Physiol 2014;307:C39-54
19. Ohira T, Arita M, Omori K, Recchiuti A, Van Dyke TE, Serhan CN. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem 2010;285:3451-61
20. El Kebir D, Gjorstrup P, Filep JG. Resolvin E1 promotes phagocytosisinduced neutrophil apoptosis and accelerates resolution of pulmonary inflammation. Proc Natl Acad Sci USA 2012;109:14983-8
21. Chiu C-Y, Gomolka B, Dierkes C, Huang NR, Schroeder M, Purschke M, Manstein D, Dangi B, Weylandt KH. Omega-6 docosapentaenoic acid-derived resolvins and 17-hydroxydocosahexaenoic acid modulate macrophage function and alleviate experimental colitis. Inflamm Res 2012;61:967-76
22. Ramon S, Gao F, Serhan CN, Phipps RP. Specialized proresolving mediators enhance human B Cell differentiation to antibody-secreting cells. J Immunol 2012;189:1036-42
23. Chiang N, Hurwitz S, Ridker PM, Serhan CN. Aspirin has a genderdependent impact on antiinflammatory 15-epi-lipoxin A(4) formation-A randomized human trial. Arterioscler Thromb Vasc Biol 2006;26:e14-7
24. Claria J, Nguyen BT, Madenci AL, Ozaki CK, Serhan CN. Diversity of lipid mediators in human adipose tissue depots. Am J Physiol Cell Physiol 2013;304:C1141-9
25. González-Périz A, Horrillo R, Ferre N, Gronert K, Dong B, Moran-Salvador E, Titos E, Martinez-Clemente M, Lopez-Parra M, Arroyo V, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009;23:1946-57
26. Neuhofer A, Zeyda M, Mascher D, Itariu BK, Murano I, Leitner L, Hochbrugger EE, Fraisl P, Cinti S, Serhan CN, et al. Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. Diabetes 2013;62:1945-56